The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease


    • Younossi Z.
    • Anstee Q.M.
    • Marietti M.
    • et al.

    Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

    Nat Rev Gastroenterol Hepatol. 2018; 15: 11-20

  • The global NAFLD epidemic.

    Nat Rev Gastroenterol Hepatol. 2013; 10: 686-690

  • The top 10 causes of death. World Health Organization.

  • NAFLD as a driver of chronic kidney disease.

    J Hepatol. 2020; 72: 785-801

    • Targher G.
    • Chonchol M.B.
    • Byrne C.D.

    CKD and nonalcoholic fatty liver disease.

    Am J Kidney Dis. 2014; 64

    • Xie Y.
    • Bowe B.
    • Mokdad A.H.
    • et al.

    Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.

    Kidney Int. 2018; 94: 567-581

    • Chalasani N.
    • Younossi Z.
    • Lavine J.E.
    • et al.

    The diagnosis and management of nonalcoholic fatty liver disease: Practice Guidance from the American association for the study of liver diseases.

    Hepatology. 2017; https://doi.org/10.1002/hep.29367/suppinfo

    • Park C.C.
    • Nguyen P.
    • Hernandez C.
    • et al.

    Magnetic resonance elastography vs transient elastography in detection of fibrosis and Noninvasive Measurement of steatosis in patients with biopsy-Proven nonalcoholic fatty liver disease.

    Gastroenterology. 2017; 152: 598-607.e2

    • Mikolasevic I.
    • Orlic L.
    • Franjic N.
    • et al.

    Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease – where do we stand?.

    World J Gastroenterol. 2016; 22: 7236-7251

    • Imajo K.
    • Kessoku T.
    • Honda Y.
    • et al.

    Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography.

    Gastroenterology. 2016; 150: 626-637.e7

    • Newsome P.N.
    • Sasso M.
    • Deeks J.J.
    • et al.

    FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.

    Lancet Gastroenterol Hepatol. 2020; 5: 362-373

    • Harrison S.A.
    • Ratziu V.
    • Boursier J.
    • et al.

    A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.

    Lancet Gastroenterol Hepatol. 2020; 5: 970-985

    • Kaswala D.H.
    • Lai M.
    • Afdhal N.H.

    Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016.

    Dig Dis Sci. 2016; 61: 1356-1364

    • Kiapidou S.
    • Liava C.
    • Kalogirou M.
    • et al.

    Chronic kidney disease in patients with non-alcoholic fatty liver disease: what the Hepatologist should know?.

    Ann Hepatol. 2020; 19: 134-144

    • Musso G.
    • Gambino R.
    • Tabibian J.H.
    • et al.

    Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

    PLoS Med. 2014; 11https://doi.org/10.1371/journal.pmed.1001680

    • Mantovani A.
    • Byrne C.D.
    • Bonora E.
    • et al.

    Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis.

    Diabetes Care. 2018; 41: 372

    • Mantovani A.
    • Zaza G.
    • Byrne C.D.
    • et al.

    Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis.

    Metab Clin Exp. 2018; 79: 64-76

    • Sinn D.H.
    • Kang D.
    • Jang H.R.
    • et al.

    Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study.

    J Hepatol. 2017; 67: 1274-1280

    • Targher G.
    • Bertolini L.
    • Rodella S.
    • et al.

    Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

    Clin J Am Soc Nephrol. 2010; 5: 2166-2171

    • Yeung M.-W.
    • Wong G.L.-H.
    • Choi K.C.
    • et al.

    Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes.

    J Hepatol. 2018; 68https://doi.org/10.1016/j.jhep.2017.09.020

    • Kasapoglu B.
    • Turkay C.
    • Yalcın K.S.
    • et al.

    Increased microalbuminuria prevalence among patients with nonalcoholic fatty liver disease.

    Ren Fail. 2016; 38: 15-19

    • Cullaro G.
    • Verna E.C.
    • Lee B.P.
    • et al.

    Chronic kidney disease in liver transplant Candidates: a rising burden impacting post–liver transplant outcomes.

    Liver Transplant. 2020; 26https://doi.org/10.1002/lt.25694

    • Hydes T.
    • Buchanan R.
    • Kennedy O.J.
    • et al.

    Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease.

    BMJ Open. 2020; 10: e040970

  • Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.

    Nat Rev Nephrol. 2017; 13: 297-310

    • Musso G.
    • Cassader M.
    • Cohney S.
    • et al.

    Emerging liver-kidney interactions in nonalcoholic fatty liver disease.

    Trends Mol Med. 2015; 21: 645-662

    • Kanbay M.
    • Bulbul M.C.
    • Copur S.
    • et al.

    Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

    J Nephrol. 2020; https://doi.org/10.1007/s40620-020-00751-y

    • Fan C.Y.
    • Wang M.X.
    • Ge C.X.
    • et al.

    Betaine supplementation protects against high-fructose-induced renal injury in rats.

    J Nutr Biochem. 2014; 25: 353-362

    • García-Ruiz C.
    • Fernández-Checa J.C.

    Mitochondrial oxidative stress and antioxidants balance in fatty liver disease.

    Hepatol Commun. 2018; 2: 1425-1439

    • Wang C.
    • Cui Y.
    • Li C.
    • et al.

    Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet.

    Lipids Health Dis. 2013; 12https://doi.org/10.1186/1476-511X-12-165

    • Ruiz S.
    • Pergola P.E.
    • Zager R.A.
    • et al.

    Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.

    Kidney Int. 2013; 83: 1029-1041

    • Pergola P.E.
    • Raskin P.
    • Toto R.D.
    • et al.

    Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

    N Engl J Med. 2011; 365: 327-336

    • Pal D.
    • Dasgupta S.
    • Kundu R.
    • et al.

    Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance.

    Nat Med. 2012; 18: 1279-1285

    • Agarwal S.
    • Chattopadhyay M.
    • Mukherjee S.
    • et al.

    Fetuin-A downregulates adiponectin through Wnt-PPARγ pathway in lipid induced inflamed adipocyte.

    Biochim Biophys Acta – Mol Basis Dis. 2017; 1863: 174-181

  • Klotho/FGF23 Axis in chronic kidney disease and cardiovascular disease.

    Kidney Dis. 2017; 3: 15-23

    • Mouzaki M.
    • Comelli E.M.
    • Arendt B.M.
    • et al.

    Intestinal microbiota in patients with nonalcoholic fatty liver disease.

    Hepatology. 2013; 58: 120-127

    • Raman M.
    • Ahmed I.
    • Gillevet P.M.
    • et al.

    Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.

    Clin Gastroenterol Hepatol. 2013; 11: 868-875.e3

    • Sampaio-Maia B.
    • Simões-Silva L.
    • Pestana M.
    • et al.

    Chapter three – the role of the gut microbiome on chronic kidney disease.

    in: Sariaslani Sima Gadd Geoffrey 96. Advances in Applied Microbiology,
    Online2016: 65-94

    • Nallu A.
    • Sharma S.
    • Ramezani A.
    • et al.

    Gut microbiome in chronic kidney disease: challenges and opportunities.

    Translational Res. 2017; 179: 24-37

    • Wang Z.
    • Klipfell E.
    • Bennett B.J.
    • et al.

    Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.

    Nature. 2011; 472: 57-63

    • Musso G.
    • Cassader M.
    • Cohney S.
    • et al.

    Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities.

    Diabetes Care. 2016; 39: 1830-1845

    • Vespasiani-Gentilucci U.
    • Gallo P.
    • Picardi A.

    The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention.

    Arch Med Sci. 2018; 14: 701-706

    • Psichas A.
    • Sleeth M.L.
    • Murphy K.G.
    • et al.

    The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents.

    Int J Obes. 2015; 39: 424-429

    • Zeng H.
    • Umar S.
    • Rust B.
    • et al.

    Secondary bile acids and short chain fatty acids in the colon: a Focus on colonic microbiome, cell proliferation, inflammation, and cancer.

    Int J Mol Sci. 2019; 20: 1214

    • Tucker P.S.
    • Dalbo V.J.
    • Han T.
    • et al.

    Clinical and research markers of oxidative stress in chronic kidney disease.

    Biomarkers. 2013; 18: 103-115

    • Arman M.
    • Payne H.
    • Ponomaryov T.

    Role of platelets in inflammation.

    in: Payne H. The non-thrombotic role of platelets in health and disease. IntechOpen,
    UK2015 ()

    • Yang K.
    • Du C.
    • Wang X.
    • et al.

    Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease–associated thrombosis in mice.

    Blood. 2017; 129: 2667-2679https://doi.org/10.1182/blood-2016-10-744060

  • Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update.

    World J Gastroenterol. 2014; 20: 7260-7276

    • Malehmir M.
    • Pfister D.
    • Gallage S.
    • et al.

    Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

    Nat Med. 2019; 25: 641-655

    • Romeo S.
    • Kozlitina J.
    • Xing C.
    • et al.

    Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

    Nat Genet. 2008; 40: 1461-1465

    • Lonardo A.
    • Bellentani S.
    • Argo C.K.
    • et al.

    Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.

    Dig Liver Dis. 2015; 47: 997-1006https://doi.org/10.1016/j.dld.2015.08.004

    • Marchesini G.
    • Day C.P.
    • Dufour J.F.
    • et al.

    EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

    J Hepatol. 2016; 64: 1388-1402

    • Grimaudo S.
    • Pipitone R.M.
    • Pennisi G.
    • et al.

    Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease.

    Clin Gastroenterol Hepatol. 2020; 18: 935-944.e3https://doi.org/10.1016/j.cgh.2019.08.011

    • Shen J.
    • Wong G.L.-H.
    • Chan H.L.-Y.
    • et al.

    PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease.

    J Gastroenterol Hepatol. 2015; 30

    • Palmer C.N.A.
    • Maglio C.
    • Pirazzi C.
    • et al.

    Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.

    PLoS ONE. 2012; 7

    • Kan H.
    • Hyogo H.
    • Ochi H.
    • et al.

    Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus.

    Hepatol Res. 2016; 46: E146-E153

    • Nobili V.
    • Bedogni G.
    • Donati B.
    • et al.

    The I148M variant of PNPLA3 reduces the response to Docosahexaenoic acid in children with non-alcoholic fatty liver disease.

    J Med Food. 2013; 16https://doi.org/10.1089/jmf.2013.0043

    • Scorletti E.
    • Bhatia L.
    • McCormick K.G.
    • et al.

    Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease.

    Contemp Clin Trials. 2014; 37https://doi.org/10.1016/j.cct.2014.02.002

    • Dongiovanni P.
    • Petta S.
    • Mannisto V.
    • et al.

    Statin use and non-alcoholic steatohepatitis in at risk individuals.

    J Hepatol. 2015; 63: 705-712

  • PNPLA3 gene and kidney disease.

    Exploration Med. 2020; 1: 42-50

    • Trépo E.
    • Romeo S.
    • Zucman-Rossi J.
    • et al.

    PNPLA3 gene in liver diseases.

    J Hepatol. 2016; 65: 399-412https://doi.org/10.1016/j.jhep.2016.03.011

    • Radaeva S.
    • Wang L.
    • Radaev S.
    • et al.

    Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1.

    Am J Physiol Gastrointest Liver Physiol. 2007; 293: 809-816

    • de Vries A.P.J.
    • Ruggenenti P.
    • Ruan X.Z.
    • et al.

    Review fatty kidney: emerging role of Ectopic lipid in obesity-related renal disease. Vol 2.

    ()

    • Skov J.
    • Dejgaard A.
    • Frøkiær J.
    • et al.

    Glucagon-like peptide-1 (GLP-1): effect on kidney Hemodynamics and renin-angiotensin-aldosterone system in healthy men.

    J Clin Endocrinol Metab. 2013; 98: E664-E671

    • Sharma S.
    • Mells J.E.
    • Fu P.P.
    • et al.

    GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.

    PLoS ONE. 2011; 6https://doi.org/10.1371/journal.pone.0025269

    • Newsome P.N.
    • Buchholtz K.
    • Cusi K.
    • et al.

    A placebo-controlled trial of Subcutaneous semaglutide in nonalcoholic steatohepatitis.

    New Engl J Med. 2020; 384: 1113-1124

    • Armstrong M.J.
    • Houlihan D.D.
    • Rowe I.A.
    • et al.

    Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program.

    Aliment Pharmacol Ther. 2013; 37: 234-242

    • Armstrong M.J.
    • Hull D.
    • Guo K.
    • et al.

    Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

    J Hepatol. 2016; 64

    • Armstrong M.J.
    • Gaunt P.
    • Aithal G.P.
    • et al.

    Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

    The Lancet. 2016; 387: 679-690

    • Raj H.
    • Durgia H.
    • Palui R.
    • et al.

    SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review.

    World J Diabetes. 2019; 10: 114-132

  • Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease.

    Adv Ther. 2021; 38: 2201-2212



  • Source link
    #Interplay #Nonalcoholic #Fatty #Liver #Disease #Kidney #Disease

    Leave a Reply

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    %d bloggers like this: